Kernal Biologics

𝐀𝐈 𝐱 𝐁𝐢𝐨 𝐒𝐮𝐦𝐦𝐢𝐭: Kernal Biologics co-founder Yusuf Erkul describes designing mRNA therapies that are selectively delivered to, and translated by, specific cells in the body. He explains the four components that go into getting mRNA to the right location in the body and to be translated in the right cells, and how technology is allowing the company to do this work today. Full video: https://lnkd.in/gK7MVivp BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

I had the pleasure to sit down with Brad Loncar of BiotechTV at the AI x Bio Summit in New York Stock Exchange today. We discussed our cutting-edge work on next generation mRNA LNP therapeutics at Kernal Biologics. Many thanks to the organizers Pablo Lubroth and Amee Kapadia and hosts Decoding Bio Hummingbird Ventures Cantos and NYSE for putting together another great summit this year! Also a big shoutout to the sponsors Bunsen, McKinsey & Company, HSBC, Orrick, Herrington & Sutcliffe LLP and Amazon Web Services (AWS)!

𝐀𝐈 𝐱 𝐁𝐢𝐨 𝐒𝐮𝐦𝐦𝐢𝐭: Kernal Biologics co-founder Yusuf Erkul describes designing mRNA therapies that are selectively delivered to, and translated by, specific cells in the body. He explains the four components that go into getting mRNA to the right location in the body and to be translated in the right cells, and how technology is allowing the company to do this work today. Full video: https://lnkd.in/gK7MVivp BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

Cafer Ozdemir, PhD, Co-founder & Director of Convergence Science at Kernal Bio, gave a great presentation today at the 11th International mRNA Health Conference in Berlin, Germany. The title of his talk was "Engineering Synthetic mRNAs That Are Selectively Translated In Cancer Cells."

Kernal Bio to Present at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting! Matthew Strout will be presenting recent data on KR-336 and peripheral LNPs. Data Support Use of Onco-selective mRNA LNPs as a Novel, Promising Modality for Systemic Immuno-oncology Applications. https://lnkd.in/e6CrMHcc